Download App

Log in to access Online Inquiry
Company Overview More
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
CEO: Kummeth, Charles R.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

TECH Bio-Techne
364.510-1.840-0.50%
Post Mkt Price
364.51000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/03/31(Q2)2021/12/31(Q1)2021/09/30(FY)2021/06/30
Assets
Current assets
Cash, cash equivalents and short term investments
-16.32% 231.17M -1.4% 278.98M -18.21% 235.06M -14.52% 231.55M
-Cash and cash equivalents
-13.6% 160.82M 27.98% 211.85M 15.89% 196.32M 35.78% 199.09M
-Short-term investments
-21.93% 70.35M -42.83% 67.14M -67.17% 38.74M -73.88% 32.46M
Receivables
28.08% 202.1M 19.22% 152.9M 20.31% 147.55M 18.65% 145.39M
-Accounts receivable
28.08% 202.1M 19.22% 152.9M 20.31% 147.55M 18.65% 145.39M
Inventory
16.63% 128.28M 14.32% 121.86M 10.72% 117.37M 13.18% 116.75M
Other current assets
39.75% 31.56M 51.13% 36.5M 69.24% 43.77M -30.49% 16.92M
Total current assets
4.68% 593.11M 8.91% 590.23M 0.34% 543.75M -1.98% 510.61M
Non current assets
Net PPE
4.08% 281.85M 4.68% 276.11M 6.43% 278.53M 13.47% 281.74M
-Gross PPE
6.75% 488.6M 7.2% 477.2M 8.45% 474.06M 12.79% 471.59M
-Accumulated depreciation
-10.61% -206.76M -10.86% -201.09M -11.46% -195.53M -11.79% -189.85M
Goodwill and other intangible assets
11.6% 1.38B 12.04% 1.4B 15.9% 1.44B 17.21% 1.46B
-Goodwill
10.87% 827.62M 11.44% 832.06M 14.81% 840.02M 15.76% 843.07M
-Other intangible assets
12.71% 551.34M 12.93% 569.35M 17.48% 596.3M 19.25% 615.97M
Other non current assets
296.58% 45.98M 227.24% 37.11M 12.72% 11.59M 58.82% 11.58M
Total non current assets
12.43% 1.71B 12.37% 1.71B 14.24% 1.73B 16.31% 1.75B
Total assets
10.33% 2.3B 11.46% 2.3B 10.57% 2.27B 11.61% 2.26B
Liabilities
Current liabilities
Payables
17.91% 40.65M 30.85% 43.04M 5.67% 37.13M 23.3% 38.72M
-accounts payable
19.41% 30.86M 10.32% 26.76M -5.77% 25.62M 27.26% 29.38M
-Total tax payable
174.79% 9.79M 290.49% 14.28M 201.58% 6.51M 124.58% 5.34M
-Other payable
-- -- -59.86% 2M -13.61% 5M -32.64% 4M
Current accrued expenses
28.3% 75.64M 37.12% 62.91M 42.58% 49.63M 65.69% 66.58M
Current debt and capital lease obligation
6.33% 24.36M 8.46% 24.31M 10.39% 24.5M 9.38% 24.1M
-Current debt
0% 12.5M 0% 12.5M 0% 12.5M 0% 12.5M
-Current capital lease obligation
13.92% 11.86M 19.14% 11.81M 23.79% 12M 21.68% 11.6M
Current deferred liabilities
23.47% 23.11M 44.37% 19.08M 43.93% 19.12M 45.57% 19M
Other current liabilities
19.33% 3.08M 72.68% 5.47M -- 3.61M -- 3.89M
Current liabilities
21.21% 166.84M 31.68% 154.81M 27.1% 133.99M 42.76% 152.28M
Non current liabilities
Long term debt and capital lease obligation
12.28% 302.86M 15.79% 327.34M -6.38% 352.78M -3.65% 396.45M
-Long term debt
21.48% 246.51M 23.09% 269.62M -7.53% 287.72M -4.48% 328.83M
-Long term capital lease obligation
-15.67% 56.35M -9.35% 57.72M -0.97% 65.06M 0.56% 67.63M
Non current deferred liabilities
0.91% 99.3M -3.72% 101.42M -2.53% 98.81M -7.88% 93.13M
Other non current liabilities
-46.38% 12.77M -54.46% 11.75M -33.14% 20.05M -9.23% 24.46M
Total non current liabilities
5.18% 419.73M 6.69% 447.51M -3.77% 489.24M -0.05% 539.44M
Total liabilities
9.29% 586.57M 12.16% 602.32M 1.53% 623.23M 7.01% 691.72M
Shareholders'equity
Share capital
1.03% 393K 1.29% 393K 1.81% 393K 1.3% 390K
-common stock
1.03% 393K 1.29% 393K 1.81% 393K 1.3% 390K
Retained earnings
4.04% 1.13B 3.7% 1.15B 4.28% 1.12B 2.65% 1.09B
Paid-in capital
23.73% 636.32M 28.15% 616.43M 30.13% 583.85M 27.08% 534.41M
Gains losses not affecting retained earnings
13.87% -55.15M 7.42% -59.47M 22.76% -64.22M 41.06% -57.29M
Total stockholders'equity
11.36% 1.71B 11.9% 1.7B 13.9% 1.64B 13.16% 1.56B
Noncontrolling interests
-112.42% -1.05M -105.12% -458K -- 7.59M -- 8.26M
Total equity
10.68% 1.71B 11.21% 1.7B 14.43% 1.65B 13.76% 1.57B
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%